Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study.

@article{Herrlinger2013EfficacySA,
  title={Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study.},
  author={Klaus Richard Herrlinger and Mircea Diculescu and Klaus Fellermann and Holger Hartmann and Stefanie Howaldt and Robert Nikolov and Andriy Petrov and Wolfgang Reindl and Jan M Otte and Simeon G Stoynov and Ulrike Strauch and Andreas Sturm and Radu Voiosu and Aldo Ammendola and Bruno Dietrich and Bernd Hentsch and Eduard F Stange},
  journal={Journal of Crohn's & colitis},
  year={2013},
  volume={7 8},
  pages={636-43}
}
BACKGROUND Vidofludimus (SC12267) is a novel oral immunomodulator inhibiting dihydroorotate dehydrogenase (DHODH) and the expression of proinflammatory cytokines including interleukin-17 (IL17A and IL17F) and interferon-gamma. The objective of the study was to explore the efficacy, safety and tolerability of vidofludimus in steroid-dependent inflammatory bowel disease (IBD). METHODS The open label uncontrolled ENTRANCE study (ClinicalTrials.gov NCT00820365) has been conducted at 13 study… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 33 references

Inhibition of IL-17 release by the novel anti-inflammatory drug vidofludimus involves attenuation of STAT-3 and NF-kappa B signaling pathways in murine splenocytes and hapten-induced colitis

  • LR Fitzpatrick, JS Small, A. Ammendola
  • Gastroenterology
  • 2011

SC12267, a novel inhibitor of human DHODH, in the rom https://academic.oup.com/ecco-jcc/article-abstract/7/8/636/499534 ry 2018 treatment of rheumatoid arthritis

  • C Herrlinger, B Manger, G Burmester, R Alten, S Jeka, M Lazarevic
  • Ann Rheum DisParis: Eular; June
  • 2008

Similar Papers

Loading similar papers…